Bibliography
- Martelletti P, Birbeck GL, Katsarava Z, et al. The global burden of disease survey. 2010, lifting the burden and thinking outside-the-box on headache disorders. J Headache Pain 2013;14:13
- Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011;12:570-84
- Lionetto L, Casolla B, Mastropietri F, et al. Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol 2012;8:1043-50
- Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004;56:371-81
- Shields KG, Goadsby PJ. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis 2006;23:491-501
- Tso AR, Goadsby PJ. New targets for migraine therapy. Curr Treat Options Neurol 2014;16:318
- Bell IM. Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine. J Med Chem 2014;57(19):7838-7858
- Negro A, Lionetto L, Simmaco M, et al. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs 2012;21:807-18
- Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther 2013;93:78-85
- Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 2008;28:226-36
- Edvinsson L. PACAP and its receptors in migraine pathophysiology. Br J Pharmacol 2014; [Epub ahead of print]
- Banki E, Hajna Z, Kemeny A, et al. The selective PAC1 receptor agonist maxadilan inhibits neurogenic vasodilation and edema formation in the mouse skin. Neuropharmacology 2014;85:538-47
- Rainero I, Rubino E, Paemeleire K, et al. Genes and primary headaches: discovering new potential therapeutic targets. J Headache Pain 2013;14:61
- Costa C, Tozzi A, Rainero I, et al. Cortical spreading depression as a target for anti-migraine agents. J Headache Pain 2013;14:62
- Holland PR, Akerman S, Goadsby PJ. Cortical spreading depression-associated cerebral blood flow changes induced by mechanical stimulation are modulated by AMPA and GABA receptors. Cephalalgia 2010;30:519-27
- Andreou AP1, Holland PR, Goadsby PJ. Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br J Pharmacol 2009;157:464-73
- Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012;17:393-406
- Benemei S, Fusi C, Trevisan G, et al. The TRPA1 channel in migraine mechanism and treatment. Br J Pharmacol 2014;171:2552-67
- Benemei S, De Cesaris F, Fusi C, et al. TRPA1 and other TRP channels in migraine. J Headache Pain 2013;14:71doi:10.1186/1129-2377-14-71
- Farinelli I, De Filippis S, Coloprisco G, et al. Future drugs for migraine. Intern Emerg Med 2009;4:367-73
- Cevoli S, D’Amico D, Martelletti P, et al. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia 2009;29:1285-93
- Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 2012;13:361-78